SE9303068D0 - New use - Google Patents

New use

Info

Publication number
SE9303068D0
SE9303068D0 SE9303068A SE9303068A SE9303068D0 SE 9303068 D0 SE9303068 D0 SE 9303068D0 SE 9303068 A SE9303068 A SE 9303068A SE 9303068 A SE9303068 A SE 9303068A SE 9303068 D0 SE9303068 D0 SE 9303068D0
Authority
SE
Sweden
Prior art keywords
pct
date
sec
patient
treatment
Prior art date
Application number
SE9303068A
Other languages
English (en)
Swedish (sv)
Inventor
Bengt-Aake Bengtsson
Olle G P Isaksson
Jan-Ove Johansson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9303068A priority Critical patent/SE9303068D0/xx
Publication of SE9303068D0 publication Critical patent/SE9303068D0/xx
Priority to JP7509721A priority patent/JPH09502973A/ja
Priority to PT94928538T priority patent/PT720483E/pt
Priority to ES94928538T priority patent/ES2218529T3/es
Priority to DE69433687T priority patent/DE69433687T2/de
Priority to CA002168570A priority patent/CA2168570C/en
Priority to NZ274025A priority patent/NZ274025A/en
Priority to PCT/SE1994/000875 priority patent/WO1995008345A1/en
Priority to AT94928538T priority patent/ATE263573T1/de
Priority to DK94928538T priority patent/DK0720483T3/da
Priority to AU77933/94A priority patent/AU683306B2/en
Priority to EP94928538A priority patent/EP0720483B1/de
Priority to US08/602,728 priority patent/US5736515A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9303068A 1993-09-21 1993-09-21 New use SE9303068D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9303068A SE9303068D0 (sv) 1993-09-21 1993-09-21 New use
US08/602,728 US5736515A (en) 1993-09-21 1994-09-21 Use of growth hormone for increasement of concentration of GH, IGF-I and IGFBP-3 in cerebrospinal fluid
DE69433687T DE69433687T2 (de) 1993-09-21 1994-09-21 Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
PT94928538T PT720483E (pt) 1993-09-21 1994-09-21 Utilizacao de hormona de crescimento no fabrico de um medicamento para o tratamento de lesao cerebral isquemica e demencia
ES94928538T ES2218529T3 (es) 1993-09-21 1994-09-21 Uso de la hormona del crecimiento para la produccion de un medicamento para el tratamiento de lesiones isquemicas en el cerebro y demencia.
JP7509721A JPH09502973A (ja) 1993-09-21 1994-09-21 脳脊髄液中のｇｈ，ｉｇｆ−▲ｉ▼およびｉｇｆｂｐ−３の濃度の増加のために用いる成長ホルモン
CA002168570A CA2168570C (en) 1993-09-21 1994-09-21 Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
NZ274025A NZ274025A (en) 1993-09-21 1994-09-21 Use of growth hormone for increasing the concentration of GH in cerebrospinal fluid
PCT/SE1994/000875 WO1995008345A1 (en) 1993-09-21 1994-09-21 Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid
AT94928538T ATE263573T1 (de) 1993-09-21 1994-09-21 Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
DK94928538T DK0720483T3 (da) 1993-09-21 1994-09-21 Anvendelse af væksthormon ved fremstilling af et medikament til behandling af iskæmisk hjerneödelæggelse og demens
AU77933/94A AU683306B2 (en) 1993-09-21 1994-09-21 Use of growth hormone for increasement of concentration of GH, IGF-I and IGFBP-3 in cerebrospinal fluid
EP94928538A EP0720483B1 (de) 1993-09-21 1994-09-21 Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9303068A SE9303068D0 (sv) 1993-09-21 1993-09-21 New use

Publications (1)

Publication Number Publication Date
SE9303068D0 true SE9303068D0 (sv) 1993-09-21

Family

ID=20391162

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9303068A SE9303068D0 (sv) 1993-09-21 1993-09-21 New use

Country Status (13)

Country Link
US (1) US5736515A (de)
EP (1) EP0720483B1 (de)
JP (1) JPH09502973A (de)
AT (1) ATE263573T1 (de)
AU (1) AU683306B2 (de)
CA (1) CA2168570C (de)
DE (1) DE69433687T2 (de)
DK (1) DK0720483T3 (de)
ES (1) ES2218529T3 (de)
NZ (1) NZ274025A (de)
PT (1) PT720483E (de)
SE (1) SE9303068D0 (de)
WO (1) WO1995008345A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
CN1261158C (zh) 1998-09-03 2006-06-28 诺兰兹公司 生长激素在制备用于诱导神经保护作用的药剂中的应用
EP1149583A3 (de) * 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
CA2532821A1 (en) * 2003-07-29 2005-02-17 Ares Trading S.A. Use of human growth hormone in multiple system atrophy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2974088A (en) * 1958-07-18 1961-03-07 Merck & Co Inc Method of preparing growth hormone
US3118815A (en) * 1959-09-28 1964-01-21 Upjohn Co Growth hormone and recovery thereof
CA1224432A (en) * 1982-08-17 1987-07-21 Gary N. Buell Dna sequences, recombinant dna molecules and processes for producing bovine growth hormone-like polypeptides in high yield
US4521409A (en) * 1983-10-03 1985-06-04 Cornell Research Foundation, Inc. Use of growth hormone to enhance ruminant mammary development
WO1986004308A1 (en) * 1985-01-28 1986-07-31 Seung Moon Park Lighting apparatus for wheels of vehicles
US4670249A (en) * 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
IL79681A (en) * 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
IL79765A (en) * 1985-08-23 1992-02-16 Lilly Co Eli Injectable sustained release formulations of bovine somatotropin
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
US4863736A (en) * 1987-03-16 1989-09-05 Monsanto Company Somatotropin prolonged release
NZ223842A (en) * 1988-03-10 1991-07-26 Amgen Inc Porcine growth hormone analogues, production using genetic engineering and compositions for promoting growth in mammals

Also Published As

Publication number Publication date
AU683306B2 (en) 1997-11-06
DE69433687D1 (de) 2004-05-13
CA2168570C (en) 2009-04-07
PT720483E (pt) 2004-08-31
US5736515A (en) 1998-04-07
EP0720483B1 (de) 2004-04-07
DK0720483T3 (da) 2004-08-09
ES2218529T3 (es) 2004-11-16
NZ274025A (en) 2005-03-24
ATE263573T1 (de) 2004-04-15
CA2168570A1 (en) 1995-03-30
DE69433687T2 (de) 2005-03-17
JPH09502973A (ja) 1997-03-25
EP0720483A1 (de) 1996-07-10
AU7793394A (en) 1995-04-10
WO1995008345A1 (en) 1995-03-30

Similar Documents

Publication Publication Date Title
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE288444T1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
GR3021713T3 (en) The combination of growth hormone and insulin-like growth factor-i enhances growth
EP0798000A3 (de) Behandlung von Krankheiten durch Anwendung von insulinähnlichen Wachstumsfaktoren und Analogen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DE69230040D1 (de) Biokompatibles implantat für die zeitliche abstimmung der ovulation von stuten
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
CO5090908A1 (es) Procedimiento para administrar peptidos insulinotropicos
PL320167A1 (en) 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity
NO940180D0 (no) Anvendelse av IGF-I
DE60012517D1 (de) Methoden zur behandlung von diabetes
ES2131528T3 (es) Nuevos polipeptidos y su uso.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
SE9303068D0 (sv) New use
CA2074166A1 (en) Method for treating intestinal diseases
ATE192656T1 (de) Verfahren zur behandlung von patienten mit chronischer lebererkrankung
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE69332541D1 (de) Il-6 enthaltende pharmazeutische zusammensetzungen ihre verfahren zur behandlungder verbrauchenden hämorrhagischen thrombozythämie
DE69221725D1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.